Casomorphin

Overview

Casomorphins are a family of opioid-active peptides released from β-casein during the gastrointestinal digestion of milk and dairy products. The most extensively studied member is β-casomorphin-7 (BCM-7), a heptapeptide (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) corresponding to residues 60-66 of bovine β-casein A1 variant. The family was first described by Victor Brantl, Hans Teschemacher, and colleagues in the late 1970s as part of broader research into "exorphins" — opioid peptides derived from food proteins rather than endogenous precursors.

Casomorphins bind the mu-opioid receptor with modest affinity and produce classical opioid effects in isolated tissue preparations and in rodent models, including intestinal transit slowing, analgesia, and behavioral responses. They are released by pepsin, elastase, and pancreatic proteases during digestion, with specific cleavage patterns determining whether BCM-7 or shorter forms predominate.

The research literature on casomorphins has generated substantial attention beyond opioid pharmacology because of hypothesized associations between BCM-7 release and various physiological phenomena in milk consumers. The A1/A2 β-casein dichotomy — in which the A1 variant releases more BCM-7 than the A2 variant due to a single amino acid polymorphism affecting pepsin cleavage — has been the subject of considerable research and commercial attention. This article focuses on the peptide biochemistry and pharmacology, not on clinical claims.

Structure/Sequence

Bovine β-Casomorphin-7 (BCM-7): Tyr-Pro-Phe-Pro-Gly-Pro-Ile (YPFPGPI)

• Length: 7 amino acids
• Molecular weight: ~790 g/mol
• Source: Residues 60-66 of bovine β-casein
• Related forms:
  • BCM-5: YPFPG (residues 60-64)
  • BCM-4: YPFP (residues 60-63; weak activity)
  • BCM-11: YPFPGPIPNSL (longer N/C-terminal extension)

Key Structural Features

• N-terminal tyrosine: Shared with all classical opioid peptides as the "message" residue for MOR binding
• Proline-rich backbone: Three prolines impart rigidity and restrict conformational flexibility
• Free N- and C-termini: Unlike endomorphin-1, not amidated
• A1 vs A2 variants: Bovine β-casein A1 has histidine at position 67, allowing elastase cleavage to release BCM-7 efficiently; A2 has proline at 67, reducing BCM-7 release

Species Variants

• Human β-casomorphin-7: Slightly different sequence (YPFVEPI)
• Sheep and goat: Release casomorphins with varying sequences
• A1 vs A2 bovine β-casein: Single His67Pro polymorphism alters BCM-7 yield during digestion

Mechanism of Action

Opioid Receptor Binding

BCM-7 binds mu-opioid receptor with modest affinity:

• Ki at MOR: ~100-200 nM (depending on assay)
• Weaker affinity at DOR and KOR
• Acts as partial or full agonist depending on tissue

Compared to endomorphin-1 (Ki ~0.36 nM) or morphine (Ki ~1 nM), BCM-7 is a relatively weak MOR ligand, though its effects can be measured at achievable local concentrations in the gut.

Classical Opioid Effects

• Inhibition of intestinal smooth muscle contraction (GPI assay)
• Inhibition of mouse vas deferens contractions (MVD assay)
• Central analgesia in rodents (when administered centrally, bypassing BBB limitations)
• Effects reversed by naloxone, confirming opioid receptor involvement

Peripheral Effects

• Slows gastrointestinal transit
• Modulates mucin secretion
• Affects intestinal cytokine production and epithelial function
• May influence milk-fat digestion indirectly

CNS Effects

Native BCM-7 is polar and does not efficiently cross the blood-brain barrier. Any central effects of dietary BCM-7 would depend on:

• Local concentrations
• Individual variation in intestinal permeability
• Circumventricular organ access
• Potential carrier-mediated transport (disputed)

Proteolytic Inactivation

BCM-7 is degraded by:

• Dipeptidyl peptidase IV (DPP-IV) — cleaves Tyr-Pro bond
• Aminopeptidases
• Elastase activity in pancreatic secretions

Its biological half-life in circulation is short.

Research Summary

Common Discussion Topics

1. Exorphin concept — Casomorphins are the paradigm case of "exorphins" — opioid peptides derived from food proteins. Other dietary exorphins include gluten-derived gliadorphin, spinach-derived rubiscolin, and various plant-derived opioid-like sequences. The concept broadens the biology of opioid signaling beyond endogenous peptides.

2. A1 vs A2 β-casein — The single His67Pro polymorphism in bovine β-casein creates two variants with differential BCM-7 release during digestion. This has been the subject of extensive research and commercial product development (A2-only milk) with continuing scientific debate about physiological significance.

3. Peripheral vs central effects — Because BCM-7 is a polar heptapeptide with limited BBB penetration, most of its demonstrated biology is likely peripheral — at the intestinal mucosa and enteric nervous system — rather than in the brain. Any central effects would require specific permeability conditions or transporter-mediated uptake.

4. Cryptic peptide principle — Like lactoferricin from lactoferrin and tuftsin from IgG, casomorphin exemplifies the principle that larger proteins harbor cryptic bioactive peptide modules released by proteolysis. This is a general feature of many milk and food proteins.

5. Comparison to endogenous opioids — BCM-7 shares the N-terminal tyrosine "message" motif with enkephalins, endomorphin-1, and other opioid peptides but is orders of magnitude less potent. Its physiological role likely involves local gut signaling rather than systemic opioid tone.

Related Compounds

• Endomorphin-1 — high-affinity endogenous MOR tetrapeptide
• Endomorphin — broader endomorphin family entry
• Enkephalins — endogenous DOR/MOR pentapeptides
• Lactoferricin — another milk-derived cryptic peptide with antimicrobial activity
• Dermorphin — amphibian MOR-selective tetrapeptide